Percutaneous Electrical Nerve Field Stimulator System for Functional Abdominal Pain Disorders (IB-Stim)
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity and prior authorization expectations for use of the IB-Stim percutaneous electrical nerve field stimulator in pediatric patients (age 11-18) with ROME IV–defined functional gastrointestinal disorders including IBS, for Blue Cross Blue Shield - Rhode Island Medicare Advantage and Commercial products.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial therapy - Medicare Advantage and Commercial
Percutaneous electrical nerve field stimulator system (IB-STIM) may be considered medically necessary in children and adolescents when ALL of the following criteria has been met:
chunk 3
chunk 3
chunk 3
chunk 3
Prior treatments
- Medication category: acid suppression: Trial and failure of an acid suppression agent (H2-blocker or proton pump inhibitor)
- Medication category: antispasmodics or motility agents: Trial and failure of an antispasmodic or motility medication (e.g., hyoscyamine, dicyclomine, erythromycin, linaclotide, prucalopride)
- Medication category: neuromodulators: Trial and failure of a neuromodulator (e.g., amitriptyline, nortriptyline, gabapentin, periactin, aprepitant)
chunk 3
All uses of the percutaneous electrical nerve field stimulator system (IB-Stim) that do not meet the specific pediatric medical necessity criteria listed in this policy are excluded from coverage. The policy states that such uses are "considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products."
The provided excerpt does not list any additional procedural or indication-specific exclusions beyond the statement that coverage is determined by whether the device use meets the stated medical criteria. For member-specific benefit questions, providers are advised to contact the payer’s provider call center.
For Commercial Products, use of IB-Stim that does not meet ALL of the policy’s stated criteria is explicitly described as "not medically necessary." This applies when one or more required elements—such as age, ROME IV diagnosis, exclusion of organic GI disease, symptom duration, required prior therapies, or absence of listed contraindications—are not documented.
The excerpt does not enumerate additional noncovered conditions beyond the general statement regarding services determined to be not medically necessary. It also reminds providers that if services are deemed not medically necessary (or are medically necessary but non-covered), providers may be unable to bill the member unless prior written agreement is obtained.
Any use that does not meet the specified pediatric criteria—including age 11–18 years, a documented ROME IV functional GI disorder, exclusion of organic GI disease, GI symptoms present for at least 9 months, documented failure of diet modification plus at least one medication trial in each of the three classes (acid suppression; antispasmodics/motility agents; neuromodulators), and absence of contraindications (cardiac pacemaker, hemophilia, psoriasis vulgaris)—is not covered under this policy.
Conservative Treatment and Prior Therapies
Diet modification plus failed trials of at least one medication in each of three categories (acid suppression; antispasmodics or motility agents; neuromodulators).
Prior to IB‑Stim, conservative management must include diet modification plus pharmacologic therapy with trials in each of three medication categories; all of the following must be documented:
Additional conservative treatment criteria
Additional conservative treatment considerations that should be attempted or documented prior to IB‑Stim include:
Provider Actions and Documentation Requirements
Prior authorization required (Medicare Advantage); recommended (Commercial)
Prior authorization must be obtained for Medicare Advantage Plans; prior authorization is recommended for Commercial Products.
- Applicable CPT: 64567 per policy coding guidance (see coding section).
Confirm member-specific prior authorization and benefits with payer
Verify benefits and member-specific prior authorization requirements by calling the provider call center; benefits and eligibility are determined by the member's subscriber certificate or employer agreement.
- Contact the provider call center for member-specific determination before scheduling or providing services.
Conservative pharmacotherapy and diet modification required
Before IB‑Stim, the patient must have tried and failed diet modification plus at least one medication in each of three categories: acid suppression, antispasmodics or motility agents, and neuromodulators.
- Acid suppression: H2‑blockers or proton pump inhibitors (PPIs).
- Antispasmodics/motility: hyoscyamine, dicyclomine, erythromycin, linaclotide, prucalopride.
- Neuromodulators: amitriptyline, nortriptyline, gabapentin, periactin, aprepitant.
No additional step therapy requirements specified
No step therapy protocol beyond the stated conservative treatment requirement is described in this policy excerpt.
- Follow the conservative treatment requirement outlined in the policy; no additional step sequence is specified.
Required clinical documentation to support medical necessity
Document the patient's age, ROME IV–defined diagnosis, exclusion of organic GI disease, symptom duration (at least 9 months), prior therapies and failures (diet modification plus medication trials in the three specified categories), and absence of listed contraindications.
- Contraindications to note: history of cardiac pacemaker, hemophilia, or psoriasis vulgaris.
- Include dates and outcomes of prior medication trials and diet modification efforts.
Verify benefits and eligibility with payer
For member-specific benefits and eligibility, providers must call the provider call center; the subscriber agreement/certificate or employer agreement governs coverage.
- Confirm whether prior authorization is required for the specific product and member before providing services.
Noncovered / not medically necessary if criteria not met
Use of IB‑Stim that does not meet all specified medical criteria is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products.
- Ensure all eligibility criteria (age 11–18, ROME IV diagnosis, ≥9 months of symptoms, ruled-out organic disease, required prior therapies, and absence of contraindications) are documented to avoid noncoverage.
Prior authorization requirement — important notice
Prior authorization is required for Medicare Advantage Plans and is recommended for Commercial Products (restatement of policy importance).
- Obtain prior authorization for Medicare Advantage members; for Commercial members check requirements with the payer.
Member financial responsibility if service not covered
If services are determined not to be medically necessary or are non‑covered benefits, the provider may be unable to charge the member unless the member has provided written agreement in advance to pay out‑of‑pocket.
- Obtain documented, written member consent before providing services expected to be non‑covered to avoid financial liability to the provider.
Coding and Billing
| 64567 | Percutaneous electrical nerve field stimulation, cranial nerves, without implantation (New Code Effective 1/1/2026) |
| 0720T | Percutaneous electrical nerve field stimulation, cranial nerves, without implantation (Code Deleted Effective 12/31/2025) |
Imaging and Procedural Details
IB‑Stim electrode placement: no imaging specified
No specific electrode placement imaging is required; a pen light is used with the device to visualize neurovasculature and aid electrode placement.
Imaging not required
There is no imaging requirement specified in this policy excerpt for IB‑Stim procedures.
Definitions
Frequency Limits and Device Use
Background and Rationale
Irritable bowel syndrome and related functional abdominal pain disorders are common conditions thought to arise from disordered gut–brain interaction. First-line management emphasizes diet modification and subtype-directed pharmacotherapy, with many drug options lacking pediatric FDA approval. Percutaneous electrical nerve field stimulation (IB-Stim) is a non‑implant auricular neuromodulation approach intended to modulate central pain pathways and has been studied in adolescents with IBS, but conservative therapies are expected to be tried before device therapy is considered.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.